Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-09-10, Stock:NVS, The news for the past five days is as follows:
2019-09-03: NEWS1: UK cost watchdog recommends Novartis' blindness therapy Luxturna.NEWS2: Global Blood Focuses on Lead Candidate Amid Competition.NEWS3: Global Blood Focuses on Lead Candidate Amid Competition.NEWS4: 5 Cancer-Fighting Stocks to Add to Your Portfolio.NEWS5: 5 Cancer-Fighting Stocks to Add to Your Portfolio.NEWS6: Vertex snaps up Cambridge diabetes startup Semma for $950M.NEWS7: Global Blood Focuses on Lead Candidate Amid Competition.NEWS8: 5 Cancer-Fighting Stocks to Add to Your Portfolio.NEWS9: UPDATE 1-Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals.NEWS10: Novartis's Sandoz licenses proposed multiple sclerosis biosimilar.
2019-09-04: NEWS1: SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Novartis AG.NEWS2: Why Novartis (NVS) Stock Might be a Great Pick.NEWS3: Why Novartis (NVS) Stock Might be a Great Pick.NEWS4: Novartis Inks Commercialization Deal for Tysabri Biosimilar.NEWS5: Novartis Inks Commercialization Deal for Tysabri Biosimilar.NEWS6: ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS7: Why Novartis (NVS) Stock Might be a Great Pick.NEWS8: Novartis Inks Commercialization Deal for Tysabri Biosimilar.
2019-09-05: NEWS1: ROSEN, A TOP RANKED LAW FIRM, Continues To Investigate Securities Claims Against Novartis AG – NVS.NEWS2: AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC.NEWS3: AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC.NEWS4: AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC.NEWS5: Novartis signs $840M pact with IFM Due amid fallout from AveXis deal.
2019-09-06: NEWS1: Pfizer is a Top Drugmaker: Is it the Right Time to Buy It?.NEWS2: FDA Grants Priority Review to Global Blood's SCD Candidate.NEWS3: Novartis' Capmatinib Gets Breakthrough Therapy Tag From FDA.NEWS4: Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs.NEWS5: UPDATE 1-Novartis joins Pfizer with FDA fast-track tag for lung cancer hopeful.NEWS6: 4 Biotech Stocks With Big Catalysts in September.NEWS7: 4 Biotech Stocks With Big Catalysts in September.
2019-09-09: NEWS1: Amarin: Keep Your Dry Powder Ready.NEWS2: Amarin: Keep Your Dry Powder Ready.NEWS3: This Rockville biotech has added another deal to its growth plan.NEWS4: Novartis Announces Positive Long-Term Data on Migraine Drug.NEWS5: UPDATE 1-Novartis CEO promises to speed data integrity disclosures.NEWS6: Novartis CEO pledges to speed data integrity disclosures.

Answer: Decrease